1438. Uptake of 13-Valent Pneumococcal Conjugate Vaccine in High-Risk Adults Aged 19-64 Years: A Kaplan-Meier Approach
Session: Poster Abstract Session: Pneumococcal Vaccines
Friday, October 5, 2018
Room: S Poster Hall
  • Uptake Immunosuppressed IDW_PAP7414_final.pdf (1.0 MB)
  • Background: Coverage estimates for pneumococcal vaccination in the United States (US) come from the National Health Interview Survey (NHIS) and do not differentiate between 13-valent conjugated vaccine (PCV13) and 23-valent polysaccharide vaccine (PPSV23). This study was conducted to assess coverage of PCV13 among adults aged 19-64 years targeted by the high-risk recommendation issued by the Advisory Committee on Immunization Practices (ACIP) in 2012.

    Methods: Uptake was evaluated from 10/2012 through 10/2016 in two statistically de-identified databases: Optum’s Clinformatics™ Data Mart (CDM), consisting of administrative health claims, and the Optum-Humedica Electronic Health Record (EHR) dataset, which includes EHR data from providers, primarily integrated delivery networks in the US to cover the continuum of care. Eligibility for the recommendation was determined between 10/2011 and 10/2016 and served as the index event. Post-index PCV13 uptake was evaluated using prescription and administration codes. Patients with PCV13 prior to the recommendation were excluded to minimize misclassification of PCV13 status. Uptake was calculated using a Kaplan-Meier estimator, with separate estimates for the period before and after the 2014 ACIP age-based recommendation for all adults aged ≥65 years.

    Results: Uptake of PCV13 was lower among 223,888 patients in the CDM vs. 571,993 patients in the EHR dataset, with <15% of recommended high-risk patients receiving PCV13 in the 4 years following publication of the recommendation. Vaccination among 19-64 year old high risk patients accelerated after the October 2014 publication of the recommendation for all adults aged ≥65 years. This was consistent in both CDM and EHR databases (Table 1).

    Conclusion: Uptake of PCV13 among high-risk adults aged 19-64 years in the US has been very low. Some of the PCV13 vaccination among high-risk patients may have been driven by spillover from the subsequent age-based recommendation for adults aged ≥65 years.

    Table 1. KM estimates at the end of the study with 95% CI

    Uptake Rate

    95% CI




    0.041 - 0.043



    0.079 - 0.084

    CDM (claims)



    0.018 - 0.020



    0.045 - 0.052

    Jeffrey Vietri, PhD1, Birol Emir, PhD2, James Harnett, PharmD2 and Erica Chilson, PharmD1, (1)Pfizer Inc, Collegeville, PA, (2)Pfizer Inc., New York, NY


    J. Vietri, Pfizer, Inc.: Employee and Shareholder , Salary .

    B. Emir, Pfizer Inc: Employee and Shareholder , Salary .

    J. Harnett, Pfizer Inc: Employee and Shareholder , Salary .

    E. Chilson, Pfizer Inc: Employee and Shareholder , Salary .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.